Botulism Market is segmented by By Toxin type (Type A, Type B, Type C, Type D, Type E, Type, F, Type G, Type H), By Botulism Type (Foodborne Botulism, Wound Botulism, Infant Botulism, Others (Adult intestinal colonization, Iatrogenic botulism)), By Treatment Type (Antitoxin, Antibiotics, Breathing assistance, Cathartics, Others), By End User (Hospital Pharmacies, Clinics, Retail pharmacies, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Botulism Market Overview
The Botulism Market is expected to grow at a CAGR of 7.5% during the forecast period (2024-2031). Botulism is a severe form of food poisoning induced by eating tainted food. Clostridium botulinum is a spore-forming anaerobic bacterium that may grow in food-producing toxins.
Botulinum antitoxin is generated from horse serum and has various side effects, including serum sickness, anaphylaxis, and the possibility of life-long sensitivity to equine proteins. Botulism inhibits nerve activity and, if left untreated for an extended time, can result in significant consequences such as death and paralysis. Vomiting, nausea, constipation, and double vision are some of the most prevalent symptoms of this illness. Botulism is most efficiently established clinically by finding botulinal toxin in the patient's blood, feces, or vomitus.
Botulism Market Summary
| Metrics | Details |
| Market CAGR | 7.5% |
| Segments Covered | By Toxin type, By Botulism Type, By Treatment Type, By Distribution Channel and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
For More Insights Request Free Sample
Botulism Market Dynamics
Botulism market is primarily driven by the increase in food poisoning, availability of efficient botulism solutions, and favorable reimbursement policies.
Approvals and product launches by the market key players are expected to drive market growth.
Sihuan Pharmaceutical Holding Group Ltd. has gained approval to market its botulinum toxin product Letybo50U in February 2021. (Type A botulinum toxin for injection). Also, Maypharm plans to launch METOX, a novel botulinum toxin, in January 2021. It is an effective treatment for moderate to severe wrinkles induced by vigorous daily face motions. In addition, Huon's Global launched Liztox, a novel botulinum toxin product, in January 2019. Liztox completed multiple clinical trials for the product the same year and got permission from the Ministry of Food and Drug Safety. Thus, from the above statements, the market is expected to drive market growth.
Restraint:
However, high-cost investments required for the treatment, strict government regulations, and the wrong diagnosis are expected to restrain the market's growth for botulism. For instance, an Arizona company got shut down after four people got paralyzed when injected with botulin toxins that were not approved for human use.
Industry Analysis
The botulism market provides in-depth analysis of the market based on various industry factors such as porter five forces, supply chain, pricing analysis etc.
Botulism Market Segment Analysis
Antitoxins segment is expected to hold the largest market share in botulism market.
The antitoxins segment accounted for the largest market share in 2021. The segment is beneficial because of antitoxins, the main treatment for botulism. It interferes with the toxin in your bloodstream. This medication can often help stop symptoms from getting worse. For instance, BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients. Therefore, it has increased the demand for antitoxins worldwide. Thus, from the above statements, the market segment accounted for the largest market share in the forecast period.
Botulism Market Geographical Share
North American region holds the largest market share in the global botulism market
North America accounted for the largest market share in 2021. The increasing prevalence of clostridium botulinum diseases, an increase in health awareness and the availability of advanced treatment procedures in the region are the factors the market is driven in the forecast period. For instance, according to the Centers for Disease Control and Prevention, an average of 145 cases are reported annually in the United States. Approximately 15% are foodborne, 65% are baby botulism, and 20% are wound. Therefore, it has increased the adoption of antitoxin drugs in the region. Thus, from the above statements, the North American region accounted for the largest market share in the forecast period.
Botulism Companies and Competitive Landscape
Major key players in the botulism market are Allergan Inc., Emergent BioSolutions Inc., Galderma S. A, Ipsen Technologies Pvt. Ltd, Valeant Pharmaceuticals Inc., AlphaVax Inc., Merz Pharma GmbH, Revance Therapeutics Inc., Microbiotix Inc., and XOMA Corporation.
Emergent BioSolutions Inc:
Overview:
Emergent BioSolutions Inc is a life sciences firm that develops products to address medical needs and public health issues (PHTs). Its solutions prevent PHTs such as chemical, biological, radiological, nuclear, and explosives (CBRNE), infectious illnesses, travel health, emerging health crises, and acute/emergency care. Its products include vaccines, medicines, drug-device combinations, and contract development and manufacturing services. Emergent's pipeline candidates are designed to combat dengue fever and other influenza illnesses. It also provides specialized goods to governments and businesses. The corporation sells its products through commercial sales forces and third-party distributors in the United States and Canada.
Product Portfolio:
BAT [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine)] is a mixture of immune globulin fragments indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients.
The global botulism market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.
